Europe Molecular Diagnostics Market

Europe Molecular Diagnostics Market Analysis

The Europe Molecular Diagnostics Market size is estimated at USD 3.76 billion in 2025, and is expected to reach USD 5.77 billion by 2030, at a CAGR of 8.96% during the forecast period (2025-2030).

Factors such as the increasing burden of various bacterial and viral epidemics in this region, increasing demand for point-of-care diagnostics, and recent advancements in pharmacogenomics are expected to propel market growth during the forecast period. For instance, in May 2023, the ECCMID congress ELITech Group announced the impending launch of a new high throughput sample-to-result instrument for molecular diagnostics. The company’s new high throughput approach will be based on ELITech’s proven extraction and assay technology.

Further, according to the European Alliance for Personalized Medicine December 2023 factsheet, the United Kingdom has a well-established infrastructure for NGS testing. There are dedicated NGS centers equipped with the necessary tools and infrastructure. Sufficient funding is available to develop and maintain NGS infrastructure, indicating a commitment to advancing this technology. Thus, the availability of infrastructure and advancing technology in Europe is anticipated to increase the adoption of molecular diagnostics in the region.

The market players in the region are concentrating on product and technological development and acquiring technology companies to boost market growth. For instance, in May 2024, Bruker Corporation acquired the ELITechGroup business, excluding the carved-out ELITech clinical chemistry business. ELITech provides systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology. Such developments are expected to drive the market.

Therefore, the market is anticipated to achieve high growth rates during the forecast period due to the above factors. However, the need for high-complexity testing centers is expected to hinder market growth during the forecast period.

Europe Molecular Diagnostics Market Trends

The Infectious Disease Segment is Expected to Witness High Growth During the Forecast Period

The infectious disease segment is anticipated to hold significant market shares during the forecast period. This segment is driven by the increased number of medicines developed and the European region's massive burden of infectious diseases. For instance, sexually transmitted infections (STIs) represent a significant public health problem in the United Kingdom.

According to LabMedica International, in December 2023, researchers developed a new artificial intelligence (AI)- an assisted molecular diagnostic platform that can identify infectious diseases. This cost-effective, portable device could be instrumental in curbing future pandemics due to its high accuracy and adaptability. Therefore, a rise in innovations in diagnostics of infectious diseases is expected to fuel market growth during the forecast period.

Moreover, key players in the region are expanding their regional market position by adopting various strategies, such as mergers and acquisitions, while others are developing new test methods for diagnosis and introducing new products to retain their market share. In September 2023, Professor Johnjoe McFadden's research team developed a new molecular test called "Electro-chemical LAMP" (eLAMP). This test is affordable, rapid, sensitive, and can be performed at home, in a GP surgery, or a hospital lab. eLAMP is sensitive to lab-based polymerase chain reaction (PCR) tests but can be performed at home when connected to a smartphone.

Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.

Germany is Expected to Dominate the European Molecular Diagnostics Market

Germany has a strong base of global companies working on developing molecular diagnostics due to the increasing prevalence of chronic diseases and the rising geriatric population in the country, which is more prone to several chronic diseases. This is expected to drive market growth. The increasing incidence of chronic conditions, such as cancer in Germany, is expected to contribute to the development of the market. According to the Annals of Oncology report of 2023, about 1,261,990 cancer deaths were registered for 2023 in Europe. Breast and colorectum cancer were more prevalent in females, while in males, prostate and lung cancer were more prevalent in the country. The increasing prevalence of cancer conditions among the German population led to the rise in demand for molecular diagnostics, thereby contributing to the overall market growth during the forecast period.

The country's development will drive market growth during the forecast period. For instance, in January 2024, ELITechGroup launched CE-IVDR certified GI Bacterial PLUS ELITe MGB Kit, a robust addition to its diagnostic portfolio in Germany.

Thus, owing to the above factors, the market in Germany is expected to project growth during the forecast period.

Europe Molecular Diagnostics Industry Overview

The European molecular diagnostics market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Abbott Laboratories, F Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technologies.

Europe Molecular Diagnostics Market Leaders

Europe Molecular Diagnostics Market News

• Febraury 2024: Sysmex Corporation entered a strategic alliance agreement with CellaVision AB to advance hematology solutions by expanding its portfolio, including next-generation cell morphology analyzers.
• November 2023: F Hoffmann-la Roche Ltd launched the LightCycler PRO System based on the proven gold standard technology of the LightCycler Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in vitro diagnostics.